EndoCrine Biotherapeutics

2150 Shattuck Avenue Ste. 1300


Operator of a clinical biotechnology company intended to develop new solutions to treat diabetes. The company specializes in the research and development of early-stage drug discovery of therapeutics that would improve pancreatic endocrine cell health, enabling the healthcare industry to implement advances in pancreatic stem cell differentiation and the development of human cellular models for efficient treatment.